Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


PBAC changes end in delay

Posted 7 April 2021 AM

PBAC's process improvements have the potential to delay PBS listings even further - just one problem in a system that needs to be made more robust and future fit, according to Biogen managing director Kylie Bromley.

"Certainly the Department and PBAC have made some good efforts with streamlined pathways but in some cases that has actually created potential further delays for the listing of products," she said.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
All fine, nothing to see here
How politics made a mess of the rollout
Special Report
PBAC July Agenda
Committee to assess 36 submissions
Approvals Action
First copy of gout drug
Plus new formulations of PBS-listed drugs
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas